Media headlines about Trinity Biotech (NASDAQ:TRIB) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Trinity Biotech earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.731046319352 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
- Trinity Biotech (TRIB) versus The Competition Critical Analysis (americanbankingnews.com)
- Critical Comparison: Trinity Biotech (TRIB) and Its Peers (americanbankingnews.com)
- Trinity Biotech (TRIB) Rating Increased to Hold at Zacks Investment Research (americanbankingnews.com)
- Trinity Biotech (TRIB) & Its Competitors Critical Review (americanbankingnews.com)
- Reviewing Trinity Biotech (TRIB) & Its Competitors (americanbankingnews.com)
Several analysts have commented on TRIB shares. Zacks Investment Research raised shares of Trinity Biotech from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. ValuEngine lowered shares of Trinity Biotech from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd.
Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings data on Wednesday, March 7th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.07 by $0.01. The business had revenue of $24.55 million for the quarter, compared to analyst estimates of $23.53 million. Trinity Biotech had a negative net margin of 40.62% and a positive return on equity of 2.37%. research analysts predict that Trinity Biotech will post 0.07 earnings per share for the current year.
Trinity Biotech Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.